The shadow of generic competition has repeatedly loomed above copyright’s blockbuster drug, PDE5 Inhibitor, sparking questions about the prospects of similar pharmaceutical investments. While first years saw substantial returns, the exclusivity expiration has allowed the path for cheaper substitutes, potentially reducing earnings and creating a s